$59.46
1.99% yesterday
NYSE, Nov 15, 10:00 pm CET
ISIN
US2546041011
Symbol
IRON
Sector
Industry

Disc Medicine Stock price

$59.46
+11.82 24.81% 1M
+27.60 86.63% 6M
+1.70 2.94% YTD
+7.05 13.45% 1Y
+23.66 66.09% 3Y
-43.54 42.27% 5Y
-43.54 42.27% 10Y
NYSE, Closing price Fri, Nov 15 2024
-1.21 1.99%
ISIN
US2546041011
Symbol
IRON
Sector
Industry

Key metrics

Market capitalization $1.80b
Enterprise Value $1.32b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.86
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-124.88m
Free Cash Flow (TTM) Free Cash Flow $-84.21m
Cash position $487.36m
EPS (TTM) EPS $-3.97
P/E forward negative
Short interest 5.65%
Show more

Is Disc Medicine a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Disc Medicine Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Disc Medicine forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Disc Medicine forecast:

Buy
100%

Financial data from Disc Medicine

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.17 0.17
67% 67%
-
-0.17 -0.17
67% 67%
-
- Selling and Administrative Expenses 30 30
105% 105%
-
- Research and Development Expense 94 94
40% 40%
-
-125 -125
51% 51%
-
- Depreciation and Amortization 0.17 0.17
67% 67%
-
EBIT (Operating Income) EBIT -125 -125
50% 50%
-
Net Profit -103 -103
40% 40%
-

In millions USD.

Don't miss a Thing! We will send you all news about Disc Medicine directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Disc Medicine Stock News

Neutral
GlobeNewsWire
3 days ago
WATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences:
Neutral
GlobeNewsWire
8 days ago
WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a l...
Neutral
GlobeNewsWire
12 days ago
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), supporting t...
More Disc Medicine News

Company Profile

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.

Head office United States
CEO John Quisel
Employees 74
Founded 2017
Website www.discmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today